US Bancorp’s Contineum Therapeutics CTNM Stock Holding History

US Bancorp’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.02K	Hold	123	–	–	﹤0.01%	3871
2026 Q1	$1.61K	Buy	+123	New	+$1.65K	﹤0.01%	3850

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

US Bancorp's CTNM Position: Q2 2026 in Review

US Bancorp held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 123 shares worth $2.02K. The position accounts for ﹤0.01% of the portfolio, ranked #3871.

US Bancorp first reported a position in CTNM in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

US Bancorp held 123 shares of Contineum Therapeutics worth $2.02K as of Q2 2026.
US Bancorp left its Contineum Therapeutics share count unchanged in Q2 2026.
Contineum Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3871 holding.
US Bancorp first reported a position in Contineum Therapeutics in Q1 2026 and has held it in 2 quarters since.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.